Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director · CHIEF EXECUTIVE OFFICER | August 17, 2026 | August 18, 2026 |
| Ra Pharmaceuticals, Inc.RARX · Entity 150034 | Director · 10% owner | June 20, 2017 | June 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,379 |
Reported balance
After 2026-08-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 2,230 · Balance 294,379 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.
Ra Pharmaceuticals, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $22.37 · Expires 2027-06-20 | Direct | 15,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.
F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:51 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,230 | $1.93 | $4,303.90 |
DisclosureSEC source: 0001193125-26-355764 · ownership.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,379 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 12,311 | $2.17 | $26,714.87 |
DisclosureSEC source: 0001193125-26-119705 · ownership.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,609 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Tax withholdingCommon Stock | 2,201 | $2.27 | $4,996.27 |
DisclosureSEC source: 0001193125-26-060037 · ownership.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,920 F1 · kind: The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. F2 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 912,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001193125-26-027287 · ownership.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,000 Underlying: Common Stock · 912,000 shares Expires 2036-01-25 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 597,500 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001193125-25-241381 · ownership.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,500 Underlying: Common Stock · 597,500 shares Expires 2035-10-14 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026. Read SEC document |
| September 17, 2025 Filed Sep 18, 2025 20:23 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 71,163 | $1.08 | $76,891.62 |
DisclosureSEC source: 0001193125-25-207432 · ownership.xml · nonDerivative · entry 2 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,121 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.09, inclusive. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:23 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 21,070 | $1.07 | $22,460.62 |
DisclosureSEC source: 0001193125-25-207432 · ownership.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,958 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,382 | $0.64 | $1,525.43 |
DisclosureSEC source: 0000950170-25-110099 · ownership.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,888 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001415889-25-010686 · form4-04152025_080459.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-11 F1 · derivative.exercise_date: All of the shares subject to the option vest on April 11, 2026. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:41 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008417 · form4-03182025_080326.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,270 F1 · shares: The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:20 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,159 | $1.15 | $2,483.28 |
DisclosureSEC source: 0001415889-25-005067 · form4-02212025_090215.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,270 F1 · kind: The shares were sold to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2024. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 478,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001959 · form4-01232025_110159.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,000 Underlying: Common Stock · 478,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:13 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001415889-24-028239 · form4-12042024_091258.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-01 F1 · derivative.exercise_date: Shares subject to the option vest in 30 equal monthly installments beginning on January 2, 2025. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 21:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Tax withholdingCommon Stock | 2,191 | $2.58 | $5,652.78 |
DisclosureSEC source: 0001415889-24-021471 · form4-08162024_090831.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,429 F1 · kind: The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 4,400 | $11.31 | $49,771.48 |
DisclosureSEC source: 0001415889-24-008260 · form4-03182024_080318.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,620 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option · Derivative | 190,000 | $0.00 Strike: $15.84 | $0.00 |
DisclosureSEC source: 0001415889-24-004210 · form4-02162024_110246.xml · derivative · entry 2 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004210 · form4-02162024_110246.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,220 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on August 14, 2024. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:24 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $4.92 | $0.00 |
DisclosureSEC source: 0001209191-23-049102 · doc4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2033-09-07 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on September 5, 2024 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:46 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 20,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001209191-23-039103 · doc4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 Underlying: Common Stock · 20,200 shares Expires 2033-06-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 00:26 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock (right to buy) · Derivative | 12,004 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001209191-22-037645 · doc4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2032-06-14 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 60 | $30.23 | $1,813.80 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 12 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,956 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 440 | $30.23 | $13,301.20 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 11 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,097,326 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 181 | $29.60 | $5,357.60 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 10 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 286,016 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,329 | $29.60 | $39,338.40 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 9 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,097,766 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 299 | $28.37 | $8,482.63 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 8 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 286,197 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,196 | $28.37 | $62,300.52 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 7 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,099,095 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,296 | $27.49 | $35,627.04 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 6 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 286,496 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 286,496 | $27.49 | $7,875,775.04 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 5 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,101,291 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,339 | $26.48 | $61,936.72 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 4 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 287,792 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 17,169 | $26.48 | $454,635.12 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 3 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,110,800 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,627 | $25.29 | $41,146.83 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 2 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 290,131 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 02:48 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 11,945 | $25.29 | $302,089.05 |
DisclosureSEC source: 0000899243-21-048463 · doc4.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,127,969 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 12 | $32.16 | $385.92 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 16 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,758 F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 88 | $32.16 | $2,830.08 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 15 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,139,914 F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,172 | $31.55 | $68,526.60 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 14 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,770 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $32.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 15,942 | $31.55 | $502,970.10 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 13 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,140,002 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $32.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 967 | $30.77 | $29,754.59 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 12 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 293,942 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.12 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 7,093 | $30.77 | $218,251.61 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 11 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,155,944 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.12 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,911 | $32.73 | $62,547.03 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 10 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 294,909 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 14,028 | $32.73 | $459,136.44 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 9 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,163,037 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 5,751 | $32.06 | $184,377.06 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 8 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 296,820 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 42,203 | $32.06 | $1,353,028.18 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 7 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,177,065 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,560 | $31.08 | $48,484.80 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 6 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 302,571 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 11,452 | $31.08 | $355,928.16 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 5 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,219,268 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 208 | $33.80 | $7,030.40 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 4 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 304,131 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $33.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,531 | $33.80 | $51,747.80 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 3 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,230,720 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $33.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 4,883 | $33.23 | $162,262.09 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 2 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 304,339 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 35,836 | $33.23 | $1,190,830.28 |
DisclosureSEC source: 0001209191-21-069154 · doc4.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,232,251 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 12,004 | $0.00 Strike: $59.66 | $0.00 |
DisclosureSEC source: 0001209191-21-040728 · doc4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2031-06-10 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 38,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 21 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 38,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.